Globe News Wire
21 Apr 2026, 14:30 UTC · 21w ago
Verdict
Headline takes no side. We score ITM +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Phase 3 COMPETE trial for 177 Lu-edotreotide met its primary endpoint, showing statistically significant improvement in progression-free survival (PFS) compared to everolimus.
More positive than 98% of claims this week
ITM will present quality of life data from the Phase 3 COMPETE trial at the ASCO Annual Meeting on May 30, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 62% of claims this week
177 Lu-edotreotide is currently pending review by the U.S. Food and Drug Administration (FDA).
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company is presenting positive Phase 3 trial data for its lead candidate and previously met its primary endpoint for progression-free survival.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3d ago
−4.6%
Price is moving against the score
$44.81 vs $46.98 close before publication (Apr 20) · not market-adjusted
ITM chart →
